The pathological aggregation of tau into paired helical filaments is a hallmark of several neurodegenerative diseases, including Alzheimer's disease. We have generated cell models of tau aggregation in order to study mechanisms involving abnormal changes of tau. In the cell models the repeat domain of tau (tau RD ) and some of its variants are expressed in a regulated fashion, e.g. the 4-repeat domain of tau with the wild-type sequence, the repeat domain with the K280 mutation ("pro-aggregation mutant"), or the repeat domain with additional proline mutations ("anti-aggregation mutant"). The aggregation of tau RD is toxic to the cells, but aggregation and toxicity can be prevented by low molecular weight compounds identified by a screen for inhibitors. Thus the cell models are suitable for developing aggregation inhibitor drugs and testing their cellular roles.
INTRODUCTION
A number of brain diseases, termed tauopathies, are accompanied by the aggregation of tau protein, including Alzheimer's disease, Pick's disease, frontotemporal dementias with parkinsonism (FTDP-17) [1] . Generating cell models for tau pathology is therefore an important step towards identifying the mechanisms of tau toxicity and for the development of appropriate drugs. In fact there is currently a debate on whether tau aggregation is toxic and what the nature of the responsible aggregates might be [2; 3] . We therefore generated stable cell lines that allow the inducible expression of the repeat domain of tau in three variants [4] : (a) the wildtype sequence, (b) a "pro-aggregation mutant" ( K280) which has a high tendency of aggregation, and (c) an "antiaggregation mutant" containing additional proline residues which prevent aggregation [5] . The aggregation of tau RD in the cells is toxic, but inhibitor compounds reduce aggregation and toxicity, and therefore the cell model can be used in the search for drugs for tau pathology in AD.
RESULTS AND DISCUSSION

Search for Inhibitors of Tau Aggregation
We started with a library of 200.000 compounds and carried out a screen for compounds capable to inhibit tau aggregation and to induce disassembly of tau aggregates [6] . The primary assay was based on the fluorescence of thioflavine S when it binds to PHFs. Among the substances tested, >70 compounds were able to inhibit PHF assembly and to induce PHF disassembly with 80-90% efficiency. The most active compounds belong to several chemical groups, including Nphenylamines, anthraquinones and a series of singletons. They were analyzed by various secondary assays, especially regarding their toxicity and activity in cells. The assays were extended to the four-repeat constructs K18 comprising the four repeats in the microtubule binding domain and K18 K280 (carrying one of the FTDP-17 mutations) and to full-length tau isoform htau24 (a four repeat isoform of tau lacking the two N-terminal inserts). The hexapeptide motifs PHF6 (third repeat) and PHF6* (second repeat) promote the formation of -structure
The efficiency of the compounds in vitro and their effects in cell models were improved by chemical modification in an attempt to optimize the structure-activity-relationship as well as the cell viability of the compounds. In particular we applied this approach to the chemical family of the Nphenylamines and anthraquinones which share a tricyclic aromatic ring system [6, 4] .
Cell Model of Tau Pathology
The problem of tau aggregation in the brain is particularly intriguing because, in principle, tau is a highly soluble protein. The intrinsic resistance to aggregation in cell and animal models can be circumvented by expressing variants of tau with a higher amyloidogenicity. The cell models are based on the neuroblastoma N2a cell line in which tau can be inducibly expressed by the addition of doxycyclin (tet-ON system) [4] . The cell models enable one to study the toxicity of tau to cells in the soluble or aggregated state, the appearance of tau aggregates after switching on the tau gene expression, the dissolution of tau aggregates after switching the gene expression off again, and the efficiency of low molecular weight compounds to prevent the formation of tau aggregates and dissolve them again. One variant is a cell line expressing the K280 mutant of the 4-repeat tau construct K18 because this has an unusually high tendency for aggregation [7] . After induction of K18 K280 for 5 days, one can observe thioflavin-S positive cells reporting on the formation of aggregates in the cells.
The aggregates can be analyzed further by extracting the cells with sarcosyl and separating the insoluble pellet by iodixanol density gradient centrifugation. In this way, PHFs from recombinant tau constructs can be demonstrated and identified by immuno-gold labelling.
In preparation for measuring the anti-aggregation effects of aggregation inhibitors it is necessary to determine their toxicity on cells. This can be done, for example, using the LDH release assay which reports on the leakiness of membranes in degenerating cells. Only compounds which show a low level of intrinsic cytotoxicity are suitable for determining the toxicity caused by the aggregation of tau.
The inducible N2a cell lines used in these experiments were based on the tau construct K18 which contains the 4-repeat domain of tau [4] . This domain forms the core of Alzheimer PHFs and can be polymerized into PHFs in vitro [8] . The mutation K18-K280 has an enhanced tendency to form -structure and aggregation [7] . The mutation represents one of the tau mutations of FTDP-17 [9] . In addition we generated a double proline mutant (PP -mutant) with prolines in each of the two hexapeptide motifs (I277P, I308P) that nucleate -structure. Prolines disrupt -strands and therefore inhibit aggregation [10] . Furthermore we also wanted to observe aggregation separately from the expression of tau, which can be achieved by staining with thioflavin S (ThS) [6] . Among the tau RD constructs tested, only the K280 mutant induced a strong reaction with ThS, consistent with its strong tendency for spontaneous aggregation in vitro; in contrast, there was no aggregation in cells in the case of the antiaggregation PP-mutant. The aggregates were also demonstrated by sarkosyl extraction [11] . Insoluble protein begins to appear at 1-2 weeks of tau induction. In this protein, the phosphorylated fraction remained mainly in the supernatant. This suggests that phosphorylation at KXGS motifs in the repeat domain does not enhance the tendency to aggregate, consistent with earlier findings [12] .
In order to determine whether the toxicity of tau is due to tau aggregates we expressed different tau constructs for varying periods and observed cell degeneration by the LDH assay. Expression of soluble tau RD has no noticeable effect on the viability of the cells, while in the case of the proaggregation K280 mutant the toxicity was ~2-fold higher than in the control. We conclude that the aggregation of tau RD causes toxicity to the cells. To test whether tau aggregates can be removed again, the expression of tau RD was first induced for several days by doxycyclin until aggregates were clearly present, then doxycyclin was removed. This lead to the disappearance of the aggregates, showing that aggregation is reversible. Thus, the aggregation of tau RD can be reversed by lowering its concentration, indicating that the protein subunits are exchangeable between the aggregated and soluble state.
Effects of Aggregation Inhibitor Compounds on Cells
A variety of assay conditions for tau aggregation inhibitors were tested. This was done by incubating the cells with 15 M compound, switching on the tau expression by doxycyclin, and scoring for ThS fluorescence after 5 days. The treatment of the tau-expressing cells with N-phenylamine compounds leads to a decrease of tau aggregates as shown in the ThS staining but not to a reduction of the amount of total tau.
To assess the depolymerization of aggregates, the expression of tau was induced for 5 days, then compounds were added, and the level of ThS fluorescence was measured after 2 more days. In all cell models tested the level of toxicity was correlated with aggregation; conversely, when aggregation was reduced by drugs, the toxicity was also lowered. Therefore, at least in our cell model there was a clear relationship between the two parameters (Fig. 1).   Fig. (1) . Determination of toxicity of compounds on N2a cells by the LDH assay: To analyse the cytotoxicity of the compounds an LDH-assay was performed. In comparison, the N-phenylamines B1C11, B4D3, B4A1 and B4D5 are less cytotoxic than the anthraquinones emodin, daunorubicin and PHF005 (black bars). NPhenlyamines inhibit PHF formation and disassemble preformed PHFs in N2a cells: The efficiency is around 60 to 70% for inhibition and around 40 to 45% for disassembly of tau aggregates in these cells.
In summary, we generated several cell models of tauopathy, based on the repeat domain of tau, in order to determine the mechanism and effects of tau aggregation in cells and to test the efficacy of inhibitor compounds. In the cell models, the extent of aggregation was related to its amyloidogenicity, i.e. the propensity of the protein to form -structure. Likewise, the toxicity of tau was related to the degree of aggregation. Tau aggregates were eliminated by the cells after discontinuing the expression of tau. Tau aggregates could be prevented by inhibitor drugs. These compounds also reversed the toxicity of tau aggregates. Thus, on the level of these cell models, the inhibition or reversal of tau aggregation appears to be a valid strategy for diseases involving tauopathy.
